Advertisement

Ciprofloxacin i.v.

Defining Its Role in Serious Infections

  • Christopher Garrard
Conference proceedings

Table of contents

  1. Front Matter
    Pages i-xii
  2. A. Dalhoff, S. Matutat, U. Ullmann
    Pages 1-12
  3. B. Wiedemann, B. Kratz
    Pages 13-19
  4. S. Kljucar, M. Heimesaat, A. Bauernfeind, E. von Pritzbuer, J. Timm
    Pages 63-73
  5. C. H. Nightingale, P. P. Belliveau, R. Quintiliani
    Pages 85-95
  6. G. Maschmeyer
    Pages 97-108
  7. H. Giamarellou
    Pages 109-119
  8. C. Reiter, M. Pfeiffer, R. Hullmann, P. Schacht
    Pages 131-146

About these proceedings

Introduction

On the occasion of a symposium in Salzburg, an international team of clinicians and pharmacologists presented recent results in profile efficacy, safety and therapeutic use of the antibiotic substance Ciprofloxacin. Of special interest for clinicians will be the clinical outcome in patients with nosocomial pneumonia and other infections of the lower respiratory tract.

Keywords

antibiotic antibiotics infection infections oncology outcome patients pharmacodynamics pharmacology safety

Editors and affiliations

  • Christopher Garrard
    • 1
  1. 1.John Radcliffe HospitalOxfordUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-79098-0
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-79100-0
  • Online ISBN 978-3-642-79098-0
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology